Subscribe free

HPB & Spleen ·

Predicting Recurrence in Lymph Node-Negative Pancreatic Tumors

A new risk score for lymph node-negative pancreatic neuroendocrine tumors helps identify patients at risk for recurrence and guides postoperative surveillance.

  • Recurrence rate for lymph node-negative patients was 10.6%, occurring at a median of 32.4 months post-surgery.
  • Risk factors included male sex (2.2x), tumor size ≥3 cm (2.64x), grade 2 or higher (3.70x), and lymphovascular invasion (3.84x).
  • The risk score’s performance was strong, with a c-statistic of 0.83 internally and 0.95 externally, stratifying patients into low (2.4%), moderate (9.0%), and high (27.7%) recurrence groups.

This tool supports tailored long-term surveillance strategies for higher-risk patients after surgery.

Journal Article by Ventin M, Arya S (…) Ferrone CR et 15 al. in JAMA Surg

read the whole article in JAMA Surg

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in HPB & Spleen

The latest stitches

All papers in HPB & Spleen →